IMB Dx, Inc. (KOSDAQ:461030)

Market Cap	154.90B
Revenue (ttm)	4.26B
Net Income (ttm)	-7.99B
Shares Out	14.02M
EPS (ttm)	-569.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200,993
Average Volume	406,884
Open	11,050
Previous Close	11,050
Day's Range	10,820 - 11,200
52-Week Range	7,180 - 14,430
Beta	n/a
RSI	53.95
Earnings Date	n/a

About IMB Dx

IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer ea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 461030

Financial Performance

In 2024, IMB Dx's revenue was 3.41 billion, a decrease of -15.40% compared to the previous year's 4.03 billion. Losses were -9.58 billion, -8.06% less than in 2023.